Project Grant HT94252510104
Award Date
3/1/25
Completion Date
2/28/27
Dollars Obligated
$222K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baton Rouge, LA 70803, USA
Similar Awards
This $785,833 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. Awarded to the University of Wisconsin System, the research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to disease prevention, diagnosis,...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
This federal Project Grant award, valued at $1,235,845.00 and awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The project, with a performance period from August 15, 2025 to August 14, 2028, will leverage data science methods to transform healthcare for military service members and the broader public. The...
The Department of the Army Medical Command awarded a $576,001 Project Grant to Cold Spring Harbor Laboratory to support research titled "Role of the Tumor Neuroenvironment in Prostate Cancer Metastasis." The two-year award running from August 1, 2022 to July 31, 2024 will fund research investigating the role of the tumor microenvironment in prostate cancer metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program...
The federal Project Grant award titled "PROTECT THE FRACTURE: BONE AND HARDWARE BACTERIAL BIOFILM DISPERSAL WITH ENZYMATIC DEBRIDEMENT" was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $377,932 award, which commenced on January 1, 2025 and is scheduled for completion by December 31, 2026, supports advanced biomedical research at Louisiana State University Health Sciences Center New Orleans (LSU Health...
This $159,900 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports preclinical research on brain metastases in lung cancer. The award will fund studies at the University of Illinois to develop and evaluate novel drug efficacy and resistance models for advancing the treatment of brain metastases, a significant challenge in lung cancer management. Spanning one year from August 2024 to August...
The federal Project Grant award, valued at $234,000.00 and granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research on in vivo hyperpolarized MRI of abnormal metabolism in prostate cancer. The award was made to the University of Texas at Dallas, a prominent research university, on September 1, 2025, with a performance period ending on August 31, 2027. The funded research aims to investigate innovative approaches to the...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The federal Project Grant award, with ID HT94252510182, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The $1,306,991.00 award, with a performance period from Aug 1, 2025 to Jul 31, 2029, is funding research at the University of Texas MD Anderson Cancer Center to develop organoid-based models and therapeutic approaches for TP53-mutated acute myeloid leukemia. This research aims to transform healthcare for...